Euroscreen raises 16 million in Equity Investments
Brussels, Belgium: October 2, 2015 - Euroscreen, a drug development company, announces today that they have completed a € 16 million Series B fundraising round. An existing shareholder, Pierre Drion, brought SFPI-FPIM as a new investor which together with Fund+ co-led this new investment round. The existing shareholders including Vesalius Biocapital II Partners, SRIW SA, BNP Paribas Fortis Private Equity, and another new comer as Capricorn Health-Tech Fund NV are also participating.
Euroscreen's ESN364 advanced drug candidate is progressing with very promising expectations in the treatment of menopausal Hot Flashes and other Women's Health Disorders such as, PolyCystic ovary syndrome (PCOS), Uterine Fibroids (UF) and Endometriosis.
More info on Euroscreen's website.
Next > Nexstim Plc supports 7th International Symposium on Navigated Brain Stimulation in Neurosurgery
Previous > Data Safety Monitoring Board recommends continuation of Nexstim Plcs Phase III Stroke Therapy Trial